285 related articles for article (PubMed ID: 1696820)
1. Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase.
Wright CD; Kuipers PJ; Kobylarz-Singer D; Devall LJ; Klinkefus BA; Weishaar RE
Biochem Pharmacol; 1990 Aug; 40(4):699-707. PubMed ID: 1696820
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators.
Derian CK; Santulli RJ; Rao PE; Solomon HF; Barrett JA
J Immunol; 1995 Jan; 154(1):308-17. PubMed ID: 7995950
[TBL] [Abstract][Full Text] [Related]
3. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
Hatzelmann A; Tenor H; Schudt C
Br J Pharmacol; 1995 Feb; 114(4):821-31. PubMed ID: 7539697
[TBL] [Abstract][Full Text] [Related]
5. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes.
Elks ML; Manganiello VC
Endocrinology; 1984 Oct; 115(4):1262-8. PubMed ID: 6207009
[TBL] [Abstract][Full Text] [Related]
6. Chemoattractant-induced release of elastase by tumor necrosis factor-primed human neutrophils: auto-regulation by endogenous adenosine.
Ottonello L; Amelotti M; Barbera P; Dapino P; Mancini M; Tortolina G; Dallegri F
Inflamm Res; 1999 Dec; 48(12):637-42. PubMed ID: 10669115
[TBL] [Abstract][Full Text] [Related]
7. Forskolin and phosphodiesterase inhibitors release adenosine but inhibit morphine-evoked release of adenosine from spinal cord synaptosomes.
Nicholson D; White TD; Sawynok J
Can J Physiol Pharmacol; 1991 Jun; 69(6):877-85. PubMed ID: 1717120
[TBL] [Abstract][Full Text] [Related]
8. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism.
Zhu WH; Majluf-Cruz A; Omburo GA
Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes.
Villagrasa V; Navarrete C; Sanz C; Berto L; Perpiñá M; Cortijo J; Morcillo EJ
Methods Find Exp Clin Pharmacol; 1996 May; 18(4):239-45. PubMed ID: 8803956
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
Souness JE; Hassall GA; Parrott DP
Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes.
Denis D; Riendeau D
Eur J Pharmacol; 1999 Feb; 367(2-3):343-50. PubMed ID: 10079010
[TBL] [Abstract][Full Text] [Related]
12. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction.
Muller B; Lugnier C; Stoclet JC
J Cardiovasc Pharmacol; 1990 Nov; 16(5):796-803. PubMed ID: 1703603
[TBL] [Abstract][Full Text] [Related]
13. Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim.
Cortijo J; Villagrasa V; Navarrete C; Sanz C; Berto L; Michel A; Bonnet PA; Morcillo EJ
Br J Pharmacol; 1996 Sep; 119(1):99-106. PubMed ID: 8872362
[TBL] [Abstract][Full Text] [Related]
14. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
Lavan BE; Lakey T; Houslay MD
Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
16. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
[TBL] [Abstract][Full Text] [Related]
17. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.
Souness JE; Villamil ME; Scott LC; Tomkinson A; Giembycz MA; Raeburn D
Br J Pharmacol; 1994 Apr; 111(4):1081-8. PubMed ID: 8032594
[TBL] [Abstract][Full Text] [Related]
18. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
19. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
[TBL] [Abstract][Full Text] [Related]
20. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
